Category: APRIL Newsletter

A message from the Chair: July 2020

Welcome to this edition of the APRIL Newsletter.

I would like to update everyone in relation to some issues arising from APRIL Board meetings held in April and June.

At the Board meeting held in April, the Board accepted a majority of the recommendations from the Research and Development (R&D) Advisory Committee for funding of Industry Priority and Transformational Projects – but not all of them. There were a number of issues arising that the Board felt it had to disagree with concerning the recommendations. Broadly, these fell into a couple of categories. First, there were concerns about some projects where joint funding with Australian Pork Limited was contemplated but not agreed upon, and second, a few projects fell into a category of essentially “product testing” where the Board felt APRIL investment was not warranted or of marginal value.

The APRIL Board never intends becoming a “rubber stamp” to the recommendations of the R&D Advisory Committee, but nor do we want to routinely reject projects that have already had so much work put into them. Besides the obvious work of the researchers/research teams in writing up significant proposals, APRIL is privileged to have a very willing group of reviewers. Some projects have had as many as 10 scientific reviews before reaching the R&D Advisory Committee Subcommittee, then the full R&D Advisory Committee, and then the Board, and yet the Board has not felt confident to invest in them. Why is this happening?

The Board decided on three actions to try and make the process smoother in the future. These are:

  • Undertake a review of the APRIL processes associated with the submission of research projects. We have now completed this internal review and at its June meeting, the Board has asked the CEO to introduce a preliminary research proposal (if applicable) to provide an opportunity for feedback before researchers or reviewers have put in many hours of effort; we have also decided to discontinue the R&D Advisory Committee Subcommittee. We felt this step would empower the full R&D Advisory Committee and eliminate “double handling” of the applications;
  • Greater coordination between APRIL and APL. Margo Andrae, John Pluske and I will look at how we might achieve tighter coordination of projects where APRIL and APL have a common interest. A number of issues arose in the Industry Priority and Transformational Project applications including possible duplication of past or current work; differing views on the relative importance to industry (both where proposals to the APRIL Board were deemed to be making a relatively simple issue into a significant and costly one, and where only a small project was addressing an issue that warrants a whole program of coordinated investment); and on budget approaches. APL has moved to appoint a Director of Research and Innovation, and the APRIL Chief Scientist/CEO will work closely with that person once in place.
  • Encouraging stronger feedback mechanisms. In this funding round, on every occasion that the Board rejected a proposal, someone had already raised our concern before it made it to the Board. Should we allow for a period of adjustment to research proposals in light of the feedback from the reviewers and/or R&D Advisory Committee? We tend to be asking our Chief Scientist to take on board too much of the feedback to develop projects, and not distinguishing between feedback that is simply helpful in project development (“you need to include another experimental treatment”) versus feedback that should either stop the proposal or trigger a major re-think (“you can buy that in Europe today” or “APL already has that information”). We need everyone involved in the process to feel empowered enough to speak up if a project proposal needs a serious re-think. In this regard, the Board is encouraging every member of the R&D Advisory Committee to voice any concerns. Managers within APRIL and APL are in a good position to see duplication or under- or over-investment in an area, and we are encouraging them to be proactive and voice concerns.

In other news, the Board was pleased with the development of the CRC-P application and the Australian Research Council-Linkage application, and felt there was real expertise and deep thinking applied to the challenges raised in the Strategic Plan. We were delighted with the successful outcome of the Linkage application and obviously disappointed by the failure of the CRC-P application to be funded. However, the CRC-P round was hyper-competitive and APRIL’s application was rated in the top quartile. It can be worked on and resubmitted for the next round, which should open very soon.

In personal news, I have resigned my full-time role with the Cooperative Research Centres’ Association (CRC-A). I hit the 10-year mark and felt it was time for someone else to take over. From now until Christmas, I’ll go part time with the CRC-A as we search for a replacement. I expect the move will give me more time for the APRIL role, and I’ll look at a few other non-executive roles. 

Dr Tony Peacock
APRIL Chair

New APRIL Industry Priority Projects

APRIL received a total of 16 Industry Priority Project proposals, one Commercialisation Project proposal, and five Transformational Project proposals from its call in late 2019/early 2020. The Board is now pleased to announce that it has approved funding for the following five Industry Priority Projects that will commence in the second half of 2020 (Covid-19 permitting):

  1. Heat tolerance (HT) in lactating sows: dietary strategies, metabolic biomarkers and microbiome signature (Project Leader: Professor Eugeni Roura, The University of Queensland).
    • Aims:
    • Test selected dietary supplements to increase the heat tolerance of the lactating sow.
    • Identify individual variations in metabolism between heat tolerant and less heat tolerant sows during lactation (metabolic and microbiome markers in resilient compared to the most vulnerable individuals).
  2. Hot and bothered! Long term impacts of late pregnancy heat stress on sows and progeny (Project Leader: Dr Kate Plush, CHM Alliance).
    • Aims:
    • Demonstrate that heat stress results in a longer duration of farrowing.
    • Identify the impacts longer farrowing duration has on (a) the sow and (b) the piglet, and how this impacts impact long term performance.
    • Test dietary/water additives for reducing farrowing duration during times of heat stress, and determine the production advantages at a commercial level.
    • Conduct a cost:benefit analysis and assessment of farrowing room cooling in the hotter months.
  3. Easing the weaning transition: large piglets from large pellets (Project Leader: Mr Robert Hewitt, CHM Alliance).
    • Aim:
    • Reduce weight variability around weaning through combining two complimentary technologies, large pellets and semi-moist extruded feed, to improve feed intake in the period immediately post-weaning, sustaining weight gain.
  4. Use of thermographic technology to detect reproductive state in sows and improve piglet performance in a commercial farrowing house [Project Leader: Dr Jessica Craig, Rivalea (Australia) Pty Ltd].
    • Aims:
    • Identify the optimum position on the sow for surface temperature measurements in order to predict success in lactation of sows, their health status, as well as the viability of their piglets at birth.
    • Early detection of at-risk piglets, farrowing difficulties, and/or MMA to provide producers with the tools for early intervention for sows and piglets at risk.
  5. Food Waste to Pig Feed – Safe and Bio-secure (Project Leader: Dr Valeria Torok, SARDI; a joint project with the Fight Food Waste CRC).
    • Aims:
    • Address novel approaches to allow increased use of food wastes in pig feed.
    • Identify food safety/biosecurity risks and strategies to mitigate perceived risks of utilising food waste streams into pig feed.
    • Identify waste streams with the least variability in quality and quantity.
    • Determine the economic feasibility of utilising food waste for pig feed in key regional production areas.

The Board also approved a Commercialisation Project submitted by Anatara Lifesciences and Ridley that will examine an in-field practical delivery mechanism (i.e., semi-moist extruded creep feed) of Anatara Lifesciences’ non-antibiotic product (bromelain) for improved post-weaning pig performance.

The successful projects demonstrated great value for money, strong industry support and application and excellent science. APRIL looks forward to these projects commencing.

Unfortunately, and as alluded to above, the APRIL-led Cooperative Research Program-Project (CRC-P) application submitted in March 2020, Pathways to rearing pigs with tails to maximise returns for pork producers, was not supported by the Australian Government. Feedback from the CRC Advisory Committee indicated that although the proposal was well articulated and presented a good potential outcome, that the partner combination was excellent and the methodology was well articulated, with good education opportunities and risk management approach, it rated less competitively than some other applications received in this round.

The application ranked in the top quartile of applications not funded; however, the overall success rate in this CRC-P round was 8%. This percentage is significantly below other competitive funding schemes that are available to APRIL, that typically range from 20-50%. This highlights not only the extremely competitive funding environment in Australia for industry-related research, but also the need for APRIL to be flexible in exploring its external funding leveraging opportunities. APRIL welcomes any feedback and suggestions for such prospects.

Successful Australian Research Council-Linkage project

The University of Queensland, The University of Melbourne, the SunPork Group and DSM, together with support from the Australasian Pork Research Institute Limited (APRIL), have secured an Australian Research Council-Linkage grant exploring the topic, ‘How to make antimicrobials in pig feed redundant, naturally’. This successful grant is another example of APRIL partnering with its members to successfully leverage external funding for a major research project of critical industry-wide importance.

The project will address a major concern in pork production, which relates to the use of in-feed antimicrobials and the association with the development of antimicrobial resistant pathogens in pigs. The overall aim of the project is to develop nutritional strategies aimed at reducing antimicrobial use in piglet feeds. The project will consist of developing a novel nutritional strategy of naturally (through maternal conditioning) boosting the natural appetite and the capacity to digest nutrients in piglets early in life. The anticipated outcome is that the new perinatal program will result in minimal bacterial proliferation and diarrhoea, minimising the need for in-feed antimicrobials in piglets.

Chief Investigators on the project are Professor Eugeni Roura, Professor Mike Gidley and Associate Professor Pat Blackall (Queensland Alliance for Agriculture and Food Innovation, The University of Queensland), and Professor Frank Dunshea (Faculty of Veterinary and Agricultural Sciences, The University of Melbourne).

In-kind contributions from the SunPork Group will include expertise in pig feed formulation and pig husbandry practices, including advice on responsible antimicrobial use and advice concerning the selection of grains and pulses for the in vitro work. The involvement of DSM, a global animal nutrition and health solutions company, will be key to novel developments in the use of exogenous enzymes and feed additives (gut environment modifiers). The project will count on the expertise of DSM’s technical team lead by Dr Aaron Cowieson, Dr Anna-Maria Kluenter, Dr Maria Walsh and Geoff Handley.

Total cash funding for the 4-year project is $2,027,819, with the Australian Research Council contributing $852,000 and partners contributing an additional $1,175,519, of which $359,223 derives from APRIL. The total value of the project (cash plus in-kind contributions) is $3,835,847.